Defining a new era of oligonucleotides

Defining a new era of oligonucleotides

Investor Inquiries

Kate Rausch
Investor Relations
617-949-4827
InvestorRelations@wavelifesci.com
Information request >

Email Alerts

Sign up here to receive email alerts from Wave Life Sciences.

Press Releases

Press Releases

Wave Life Sciences to Present at 6ᵗʰ Annual Evercore ISI HealthCONx Conference

Wave Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update

Wave Life Sciences Third Quarter 2023 Financial Results Scheduled for November 9, 2023

Wave Life Sciences Highlights Growth Strategy for Building the Leading RNA Medicines Company in Annual R&D Day

Wave Life Sciences to Present at the Chardan 7th Annual Genetic Medicines Conference

Wave Life Sciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-006, the First-ever RNA Editing Clinical Candidate, and Plans for Upcoming Virtual “R&D Day”

Wave Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business Update

Wave Life Sciences Second Quarter 2023 Financial Results Scheduled for August 3, 2023

Wave Life Sciences Joins the Russell 2000® and Russell 3000® Indexes